Resumo (PT):
Abstract (EN):
<jats:p>Dear Editor: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4R¿, anti-IL5R, anti-IL5 and anti-IgE) opened a new treatment field for patients refractory to first-line treatments (2,3).</jats:p>
Language:
English
Type (Professor's evaluation):
Scientific
No. of pages:
7